nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.02.2009 | Original Article

Measurement of central µ-opioid receptor binding in vivo with PET and [¹¹C]carfentanil: a test–retest study in healthy subjects

verfasst von: Jussi Hirvonen, Sargo Aalto, Nora Hagelberg, Anu Maksimow, Kimmo Ingman, Vesa Oikonen, Jussi Virkkala, Kjell Någren, Harry Scheinin

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

[¹¹C]Carfentanil has been widely used in positron emission tomography (PET) studies for measuring µ-opioid receptor binding in humans, but the reproducibility of the binding parameter estimates is unknown.

Materials and methods

Eight healthy volunteers were scanned twice during the same day with [¹¹C]carfentanil PET, and binding to receptors was assessed with both reference tissue and arterial plasma input-based models using region of interest (ROI) and voxel-based quantification.

Results

The two-tissue compartmental model distribution volume (V_T) was highly reproducible as indicated by low variability (VAR < 6%) and high intraclass correlation coefficients (ICC > 0.93). BP_ND (BP relative to the nondisplaceable tissue compartment) was also highly reproducible (VAR < 10%, ICC > 0.90) both at ROI- and voxel-level, and reference tissue-based models provided stable estimates after 40 min.

Conclusions

The reproducibility of [¹¹C]carfentanil binding parameter estimates is excellent with outcome measures based on both arterial plasma and reference tissue input, and a scanning time of 40 min appears sufficient.

Frost JJ, Wagner HN Jr, Dannals RF, Ravert HT, Links JM, Wilson AA et al. Imaging opiate receptors in the human brain by positron tomography. J Comput Assist Tomogr 1985;9:231–6.PubMedCrossRef

Frost JJ, Douglass KH, Mayberg HS, Dannals RF, Links JM, Wilson AA et al. Multicompartmental analysis of [11C]-carfentanil binding to opiate receptors in humans measured by positron emission tomography. J Cereb Blood Flow Metab 1989;9:398–409.PubMed

Endres CJ, Bencherif B, Hilton J, Madar I, Frost JJ. Quantification of brain mu-opioid receptors with [11C]carfentanil: reference-tissue methods. Nucl Med Biol 2003;30:177–86.PubMedCrossRef

Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood-sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834–40.PubMedCrossRef

Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage 1996;4:153–8.PubMedCrossRef

Henriksen G, Willoch F. Imaging of opioid receptors in the central nervous system. Brain 2008;131:1171–96.PubMedCrossRef

Larsen P, Ulin J, Dahlström K, Jensen M. Synthesis of [¹¹C]methyl iodide by iodination of [¹¹C]methane. Appl Radiat Isot 1997;48:153–7.CrossRef

Någren K, Truong P, Helin S, Amir A, Halldin C. Experience from two systems for recirculating production of [¹¹C]methyl iodide from target produced [¹¹C]methane. J Labelled Compds Radiopharm 2003;46(Suppl. 1):S76.

Ingman K, Hagelberg N, Aalto S, Någren K, Juhakoski A, Karhuvaara S et al. Prolonged central µ-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology 2005;30:2245–53.PubMedCrossRef

10.

Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith C, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 1995;2:189–210.CrossRef

11.

Zhou Y, Brasic J, Endres CJ, Kuwabara H, Kimes A, Contoreggi C et al. Binding potential image based statistical mapping for detection of dopamine release by ¹¹C-raclopride dynamic PET. NeuroImage 2002;16:S91.

12.

Zhou Y, Brasic JR, Ye W, Dogan AS, Hilton J, Singer HS et al. Quantification of cerebral serotonin binding in normal controls and subjects with Tourette’s syndrome using [11C]MDL 100,907 and (+)[11C]McN 5652 dynamic PET with parametric imaging approach. NeuroImage 2004;22(Suppl 2):T98.

13.

Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007;279:1533–9.CrossRef

14.

Heinz A, Reimold M, Wrase J, Hermann D, Croissant B, Mundle G et al. Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry 2005;62:57–64.PubMedCrossRef

15.

Meyer JH, Gunn RN, Myers R, Grasby PM. Assessment of spatial normalization of PET ligand images using ligand-specific templates. NeuroImage 1999;9:545–53.PubMedCrossRef

16.

Salmi E, Laitio RM, Aalto S, Maksimow AT, Långsjö JW, Kaisti KK et al. Xenon does not affect gamma-aminobutyric acid type A receptor binding in humans. Anesth Analg 2008;106:129–34.PubMedCrossRef

17.

Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 2006;67:1575–80.PubMedCrossRef

18.

Hirvonen J, Johansson J, Teräs M, Oikonen V, Lumme V, Virsu P et al. Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [(11)C]PE2I: quantitative modeling and test–retest reproducibility. J Cereb Blood Flow Metab 2008;28(5):1059–69.PubMedCrossRef

19.

Sprenger T, Berthele A, Platzer S, Boecker H, Tolle TR. What to learn from in vivo opioidergic brain imaging? Eur J Pain 2005;9:117–21.PubMedCrossRef

20.

Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS et al. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 1996;48:567–92.PubMed

21.

Contet C, Kieffer BL, Befort K. Mu opioid receptor: a gateway to drug addiction. Curr Opin Neurobiol 2004;14:370–8.PubMedCrossRef

22.

Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl) 1997;129:99–111.CrossRef

23.

Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM et al. Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science 2001;293:311–5.PubMedCrossRef

24.

Zubieta JK, Ketter TA, Bueller JA, Xu Y, Kilbourn MR, Young EA et al. Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. Arch Gen Psychiatry 2003;60:1145–53.PubMedCrossRef

25.

Slifstein M, Laruelle M. Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl Med Biol 2001;28:595–608.PubMedCrossRef

26.

Slifstein M, Parsey RV, Laruelle M. Derivation of [(11)C]WAY-100635 binding parameters with reference tissue models: effect of violations of model assumptions. Nucl Med Biol 2000;27(5):487–92.PubMedCrossRef

Titel: Measurement of central µ-opioid receptor binding in vivo with PET and [11C]carfentanil: a test–retest study in healthy subjects
verfasst von: Jussi Hirvonen
Sargo Aalto
Nora Hagelberg
Anu Maksimow
Kimmo Ingman
Vesa Oikonen
Jussi Virkkala
Kjell Någren
Harry Scheinin
Publikationsdatum: 01.02.2009
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2009
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-008-0935-6

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2009

Comment on: Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective

Observer variation in FDG PET-CT for staging of non-small-cell lung carcinoma

FDG PET/CT findings in secondary hyperparathyroidism not mimicking multiple bone metastases

Structural alterations of the coronary arterial wall are associated with myocardial flow heterogeneity in type 2 diabetes mellitus

Imaging of deep venous thrombosis in patients using a radiolabelled anti-D-dimer Fab′ fragment (99mTc-DI-DD3B6/22-80B3): results of a phase I trial

Multimodality molecular imaging — from target description to clinical studies